Drugs / SP-420
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04741542 | Mar 2021 → Jan 2024 | disorder of iron metabolism and transport | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 1 | NCT02274233 | Oct 2014 → Sep 2015 | beta thalassemia, disorder of iron metabolism and transport | Sideris Pharmaceuticals | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05693909 | Sep 2023 → Oct 2027 expected | beta-thalassemia major, myelodysplastic syndrome | Pharmacosmos A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT03801889 | Aug 2020 → Sep 2022 | beta thalassemia, disorder of iron metabolism and transport | Abfero Pharmaceuticals, Inc | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-420 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03801889 ↗ |
| Modality | Small molecule | — CHEMBL1092665 ↗ |
| Route | Oral | “Self-administered by mouth” NCT03801889 ↗ |